Home > Insider Trading > Filing (0001553878-18-000032)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178670	Alnylam Pharmaceuticals Inc.	ALNY	Pharmaceutical Preparations (2834)	770602661

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1446125	Yvonne Greenstreet	300 Third Street Cambridge MA 02142	Evp, Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-03-26	7,221	$42.22	7,221	No	4	M	Direct
Common Stock	Disposition	2018-03-26	4,308	$136.00	2,913	No	4	S	Direct
Common Stock	Disposition	2018-03-26	2,394	$137.09	519	No	4	S	Direct
Common Stock	Disposition	2018-03-26	419	$137.78	100	No	4	S	Direct
Common Stock	Disposition	2018-03-26	100	$141.47	0	No	4	S	Direct
Common Stock	Acquisiton	2018-03-26	233	$0.00	233	No	4	J	Indirect	by Managed Account

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	J	Indirect	by Managed Account

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2018-03-26	7,221	$0.00	7,221	$42.22

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
17,779		2026-12-20	No	4	M	Direct

Footnotes

All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 17, 2018.
Sales prices ranged from $135.53 to $136.51.
Sales prices ranged from $136.61 to $137.58.
Sales prices ranged from $137.68 to $137.99.
Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.